Graft rejection and graft failure are serious complications after allogeneic stem cell transplantation (SCT). We report a patient with CML in first chronic phase who finally engrafted with a transplant from an HLA-identical unrelated donor after graft failures from two related HLA-mismatched sibling donors. After failure of one BM and two PBSC grafts from two 1 HLA-antigen mismatched related donors, the patient was finally successfully transplanted from a subsequently identified HLAidentical unrelated donor (donor 3). At 5 years post transplant, the patient is in complete cytogenetic and molecular remission. Bone Marrow Transplantation (2002) 32, 729-731. doi:10.1038/sj.bmt.1704191 Keywords: allogeneic haematopoietic stem cell transplantation; graft failure; CML; HLA disparity Graft failure -persistent marrow aplasia without any sign of haematopoietic recovery -is a serious complication after allogeneic stem cell transplantation (SCT). Many mechanisms have been reported to contribute to graft rejection (underlying disease, conditioning regimen, degree of HLA disparity, number of transplanted stem cells and residual T cells).
Graft failure -persistent marrow aplasia without any sign of haematopoietic recovery -is a serious complication after allogeneic stem cell transplantation (SCT). Many mechanisms have been reported to contribute to graft rejection (underlying disease, conditioning regimen, degree of HLA disparity, number of transplanted stem cells and residual T cells). [1] [2] [3] Following allogeneic BMT from an HLA-identical sibling, the incidence of graft rejection/failure is 2% and increases if donors are incompatible at one HLA locus. 4 The incidence of graft rejection/failure following HLAmatched unrelated BMT was described to be 10-30%, and is as high as 50-75% among recipients of HLA-nonidentical T cell-depleted marrow. [5] [6] [7] The outlook is poor for patients with primary graft failure due to infectious complications.
Here, we report a patient who experienced graft failure of three allogeneic SCT (BM and PBSC) from two different HLA-mismatched related donors and achieved successful long-term engraftment from an HLA-matched unrelated donor.
Case report
A 21-year-old male patient with Ph+ CML commenced on hydroxyurea in February 1996, followed by interferon alpha. Interferon was stopped after 3 weeks when he developed a Guillain-Barre syndrome (tetraparesis, respiratory insufficiency). After complete recovery an allogeneic stem cell transplant was planned.
The brother and sister of the patient were found to be HLA-identical to each other, but were only five out of six HLA matched to the patient. With serious side effects from standard IFN and lack of a suitable HLA-identical unrelated donor at that time, the brother was selected for bone marrow harvest. Antimicrobial prophylaxis was performed as described previously. 8 For conditioning, the patient received oral busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg). GVHD prophylaxis included CSA and ATG (40 mg/kg). The patient received 3.7 Â 10 8 /kg MNCs, and G-CSF was started post transplant. On day +22, a bacteraemia with Staphylococcus epidermidis was successfully treated with imipenem/vancomycin. When granulocytopenia o100/ml persisted for more than 26 days, graft failure was diagnosed and confirmed by bone marrow cytology and histology.
The patient then received a second graft, now of unseparated PBSC from the same donor (donor 1) after conditioning with prednisolone (4 Â 1 mg/kg) and OKT3. A total of 7.2 Â 10 6 CD34+cells/kg (1.5 Â 10 8 CD3+cells/ kg) was administered. The patient developed ulceration of the facial skin on day +14 and fever on day +20 (blood samples and skin lesion positive for Staphylococcus epidermidis) and he received imipenem and clindamycin. Despite sequential IL-3 and G-CSF, failure of the second graft was confirmed by bone marrow cytology, histology and chimerism analysis. At this point, antibodies to the HLA-mismatched antigen could not been demonstrated in a lymphocytotoxic cross-match with separated donor B and T cells.
The patient underwent the third conditioning regimen (thiotepa 2 Â 350 mg, total nodal irradiation 1 Â 7.5 Gy and ALG 4 Â 1000 mg) and received unseparated PBSC from a second related donor (sister with one HLA-antigen mismatch) containing 7.4 Â 10 6 CD34+ cells/kg and 4.61 Â 10 8 CD3+ cells/kg. After the third allogeneic transplant, he developed recurrent infection with Staphylococcus epidermidis. Neutrophil engraftment was documented on day +12 with a WBC count of 1800/ml on day +16 (35% autologous cells). Despite intensified immunosuppression (2 mg/kg prednisolone), the WBC dropped o50/ml, with only autologous cells being detectable on day +31. Graft failure was again confirmed by cytological and histological analysis of the bone marrow.
At 4 months after the first allogeneic SCT, the patient received splenic irradiation (4 Â 2.5 Gy), cyclophosphamide (4 Â 50 mg/kg) and OKT3. On 18th March 1997, he received a bone marrow transplant from an HLA-identical unrelated donor (donor 3), who had been identified meanwhile with 3.1 Â 10 8 /kg MNCs. Neutrophil engraftment was documented on day +23 (Figure 1) , and platelet recovery on day +34. Chimeric follow-up showed 100% donor cells (unrelated donor) on day +14 and +20 post transplant. Characterization of lineage-specific chimerism is shown in Figure 2 and revealed complete chimerism (unrelated donor) for CD14+, CD15+, CD56+, CD3+and CD19+ cells. 9 The patient developed acute GVHD grade II which responded to prednisolone (2 mg/ kg).
He was monitored for CMV infection by PCR. 10 CMV PCR became positive on day +25 after the third transplant and CMV infection responded to foscarnet (2 Â 60 mg/kg). Owing to febrile neutropenia and positive PCR assay for fungal DNA, the patient received conventional (7 days) and liposomal (59 days) amphothericin B. 8 In September 1997, the patient developed chronic GVHD involving skin and liver, which was controlled with tacrolimus. In December 2000, immunosuppression was discontinued without reactivation of chronic GVHD.
At 5 years post transplant the patient shows sustained engraftment with only slightly decreased platelet counts (100000/ml).
Discussion
CML as the underlying disease as well as SCT from an HLA-mismatched donor are both well-known risk factors for graft rejection/failure. 1, 3 Therefore, serotherapy with ATG was included in the conditioning regimen to reduce the risk of graft failure. In addition, T-cell depletion or the donor marrow is clearly associated with an increased rate of graft failure that is proportional to the degree of HLA incompatibility.
11
Haematopoietic recovery is more likely with high numbers of stem cells, and leukaphereses yield more haematopoietic progenitors than those is found in the average marrow graft. It has been shown that graft failure is higher in patients after T cell-depleted BMT compared to T cell-depleted PBSCT from HLA-haploidentical family members. 12 In this patient, more than 7 Â 10 6 CD34+ unseperated PBSC were collected from the same sibling donor for the second transplant. 1, 2 To minimize organ toxicity, reconditioning consisted only of prednisolone and OKT3. After the third transplant with PBSC from donor 2, leucocyte counts rose to 4500/ml for 12 days, before graft failure recurred. At that time, an HLA-identical unrelated donor was identified and a successful BMT was performed after conditioning with OKT3 and cyclophosphamide (4 Â 50 mg/kg).
Primary graft rejection and graft failure are serious complications after allogeneic transplantation, with mortality rates of 80-95% in the 1970s and early 1980s. 13 Survival increased to around 50% after second allogeneic stem cell transplantation for graft rejection/failure in aplastic anaemia, due to better treatment options.
14 This patient underwent four allogeneic SCT within 4 months. At 5 years post transplant, he has regained immunocompetence and is in complete remission and good clinical condition.
This report demonstrates that improved antimicrobial prophylaxis and treatment and new immunosuppressive regimens including OKT3, cyclophospamide, total nodal irradiation or recently Campath allow achievement of sustained allogeneic engraftment even in patients with multiple graft rejections and prolonged pancytopenia.
